KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma […]
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people […]